Muvon Therapeutics has linked its cell therapy to a 60% drop in stress incontinence episode frequency in a small phase 2 ...

Trevi Therapeutics stock (TRVI) earns a Buy rating as Haduvio advances toward phase 3 for chronic cough in IPF. Read the full ...

Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders ...

The global T-Cell lymphoma therapeutics market size was valued at US$ 2.3 Bn in 2024 and is projected to reach US$ 5.7 Bn by ...

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire ...

INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.

To date, ETX101 has shown a favorable safety profile and has been well-tolerated across all four dose levels with no treatment-related serious adverse events (n=19). The most common treatment-related ...

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in ...

Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech ...

Early ASH 2025 data shows Incyte's INCA033989 delivers spleen, anemia and symptom improvements in mutCALR myelofibrosis.

This peer-reviewed publication marks an important milestone following initial release of study information in August 2024 (see "Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT"). The ...

When pressure rises, broad guidance is useless. Teams need a repeatable sequence they can follow when deadlines compress or ...